A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

BACKGROUND: Ruxolitinib, a selective JAK1 and JAK2 inhibitor, has clinically significant activity in myelofibrosis. METHODS: In a double-blind trial, patients with intermediate-2 or high-risk myelofibrosis were randomized to twice-daily oral ruxolitinib (n=155) or placebo (n=154). The primary endpoi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Koumenis, Iphigenia L., Sun, William, Sandor, Victor, Kantarjian, Hagop M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4822164/
https://ncbi.nlm.nih.gov/pubmed/22375971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1110557
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller